August 31, 2018 / 6:20 AM / 3 months ago

AstraZeneca's experimental lupus drug fails to meet main goal in study

Aug 31 (Reuters) - AstraZeneca’s experimental lupus drug failed to meet its main target in a late-stage clinical study treating patients with moderate to severe lupus, the British drugmaker said on Friday.

AstraZeneca’s anifrolumab, which is given intravenously, was being developed for lupus, a chronic autoimmune disease with limited treatment options. (Reporting by Justin George Varghese in Bengaluru; Editing by Amrutha Gayathri)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below